Evidence map›Paper›PMID 32434772›Full record

ArticleBMJ open diabetes research & care2020

KGF-2 and FGF-21 poloxamer 407 hydrogel coordinates inflammation and proliferation homeostasis to enhance wound repair of scalded skin in diabetic rats.

Xuanxin Yang, Rongshuai Yang, Min Chen, Qingde Zhou, Yingying Zheng, Chao Lu, Jianing Bi, Wenzhe Sun, Tongzhou Huang, Lijia Li and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Xuanxin YangDepartment of Dermatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Rongshuai YangSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Min ChenSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Qingde ZhouSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yingying ZhengSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Chao LuSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jianing BiSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Wenzhe SunSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Tongzhou HuangSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Lijia LiSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jianxiang GongSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiaokun LiDepartment of Dermatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 18858811123@126.com huiqi1976@163.com profxiaokunli@163.com.
Qi HuiSchool of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China 18858811123@126.com huiqi1976@163.com profxiaokunli@163.com.
Xiaojie WangDepartment of Dermatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 18858811123@126.com huiqi1976@163.com profxiaokunli@163.com.ORCID 0000-0001-7748-1541
Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe present study focused on the development of a poloxamer 407 thermosensitive hydrogel loaded with keratinocyte growth factor-2 (KGF-2) and fibroblast growth factor-21 (FGF-21) as a therapeutic biomaterial in a scald-wound model of type-2 diabetes in Goto-Kakizaki (GK) rats. RESEARCH DESIGN AND

methodsIn this study, a poloxamer 407 thermosensitive hydrogel loaded with KGF-2 and/or FGF-21 was prepared and its physical and biological properties were characterized. The repairing effects of this hydrogel were investigated in a scald-wound model of type-2 diabetes in GK rats. The wound healing rate, epithelialization, and formation of granulation tissue were examined, and biomarkers reflecting regulation of proliferation and inflammation were quantified by immunostaining and Western blotting. T tests and analyses of variance were used for statistical analysis via Graphpad Prism V.6.0.

resultsA 17.0% (w/w) poloxamer 407 combined with 1.0% (w/w) glycerol exhibited controlled release characteristics and a three-dimensional structure. A KGF-2/FGF-21 poloxamer hydrogel promoted cellular migration without apoptosis. This KGF-2/FGF-21 poloxamer hydrogel also accelerated wound healing of scalded skin in GK rats better than that of a KGF-2 or FGF-21 hydrogel alone due to accelerated epithelialization, formation of granulation tissue, collagen synthesis, and angiogenesis via inhibition of inflammatory responses and increased expression of alpha-smooth muscle actin (α-SMA), collagen III, pan-keratin, transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and CD31.

conclusionsA KGF-2/FGF-21 poloxamer hydrogel accelerated wound healing of scalded skin in GK rats, which was attributed to a synergistic effect of KGF-2-mediated cellular proliferation and FGF-21-mediated inhibition of inflammatory responses. Taken together, our findings provide a novel and potentially important insight into improving wound healing in patients with diabetic ulcers.

Indexed as

Diabetes Mellitus, ExperimentalPoloxamerAnimalsCell ProliferationFibroblast Growth Factor 10Fibroblast Growth FactorsHomeostasisHumansHydrogelsInflammationRatsVascular Endothelial Growth Factor AWound HealingFibroblast Growth Factor 10fibroblast growth factor 21Fibroblast Growth FactorsHydrogelsPoloxamerVascular Endothelial Growth Factor Acombination therapygrowth factor(s)type 2 diabeteswound healing

Identifiers

PMID32434772
PMCPMC7245451
OpenAlexW3028050328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.